<DOC>
	<DOCNO>NCT02104427</DOCNO>
	<brief_summary>This phase II study evaluate efficacy safety TG-0054 combine G-CSF mobilize hematopoietic stem cell patient multiple myeloma , non-Hodgkin lymphoma Hodgkin disease .</brief_summary>
	<brief_title>PD Safety TG-0054 Combined With G-CSF Multiple Myeloma , Non-Hodgkin Lymphoma Hodgkin Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Male female 18 75 year age inclusive ; Patients confirm pathology diagnosis MM , NHL HD ; Potential candidate autologous stem cell transplantation Investigator 's discretion ; &gt; 4 week since last cycle chemotherapy prior study drug administration ; Total dose melphalan receive ≦ 200 mg recent chemotherapy treatment ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Recovered acute toxic effect prior chemotherapy Investigator 's discretion ; White blood cell ( WBC ) count ≧ 3.0*10^9/L screen laboratory assessment ; Absolute neutrophil count ≧ 1.5*10^9/L screen laboratory assessment ; Platelet count ≧ 100*10^9/L screen laboratory assessment ; Serum creatinine ≦ 2.2 mg/dL screen laboratory assessment ; Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin &lt; 2 x upper limit normal ( ULN ) screen laboratory assessment ; Negative human immunodeficiency virus ( HIV ) ; Adequate cardiac pulmonary function undergo leukapheresis Investigator 's discretion ; For female , one follow criterion must fulfil : 1 . At least one year postmenopausal , 2 . Surgically sterile , 3 . Willing use doublebarrier method [ intrauterine device ( IUD ) plus condom , spermicidal gel plus condom ] contraception study Day 1 28 day last dose TG0054 ; Males must willing use reliable form contraception ( use condom partner fulfil criterion ) study Day 1 28 day last dose TG0054 ; Able provide sign informed consent . Received radiation therapy pelvis ; Received &gt; 6 cycle lenalidomide ; Evidence bone marrow involvement lymphoma NHL patient ; Failed previous stem cell collection [ fail collect 2.0*10^6 CD34+ cells/kg within 4 leukapheresis session receive granulocyte colonystimulating factor ( GCSF ) ] ; Patients undergo previous stem cell transplantation procedure ; Received GCSF within 2 week prior study drug administration ; History cancer within past 5 year exclude MM , NHL , HD , basal cell squamous cell carcinoma skin ; History hematologic disorder include bleed thromboembolic disease treat anticoagulant ; History poor uncontrollable cardiovascular pulmonary disease myocardial infarction , cardiac arrhythmia , transient ischemic attack , stroke Chronic Obstructive Pulmonary Disease ( COPD ) patient hospitalize two time year due underlying disease ; Diagnosis sickle cell anemia document sickle cell trait ; Patients proliferative retinopathy ; Uncontrollable malignancy MM , NHL HD , carcinomatous meningitis , Investigator 's discretion ; Any infection require antibiotic treatment unexplained fever 38 °C within 3 day prior dose ; Pregnant breastfeeding ; Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study ; Received investigational drug within 1 month enter study ; Received prior treatment TG0054 withdraw early study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>